Boston Scientific Corporation

The 2025 annual figures show revenue of $20.07 billion, up from $16.75 billion, and net income of $2.89 billion versus $1.85 billion. Operating cash flow of $4.53 billion was 1.57 times net income, which suggests reported 2025 earnings were largely backed by cash. The Beneish M-Score of -2.448 is below -1.78 and is not in the elevated manipulation-risk zone. This is a screening test, not a finding about the company's reporting. The Altman Z-Score of 2.78 falls in the safe zone, meaning the distress model does not flag the company. The Piotroski F-Score is 7 of 8 computable signals. It counts nine tests across profitability, leverage and operating efficiency, and this result means most of the computable tests passed. The Fog Index of 20.32 is above 18, the very hard to read band, so the MD&A demands patience from a casual reader. Equity grew to $24.23 billion from $21.77 billion. Taken together, the scores look fairly clean, but the planned Penumbra debt would equal roughly 45% of year-end 2025 equity. Meanwhile, the filing shows growth slowing in key franchises such as Electrophysiology and Urology. Readers may want to look at the Penumbra closing terms and the restructuring note in the 10-Q when the next periodic report is filed.

Catalyst.Net sales are being driven by the Cardiovascular segment, which rose 10.8% on a reported basis in the first six months of 2026 to $7.126 billion, according to the 10-Q MD&A. Management credits the coronary therapies franchise, led by the AGENT Drug-Coated Balloon, and the Electrophysiology unit, led by the Farapulse Pulsed Field Ablation System. Total net sales for the first half were $10.646 billion, up 9.5% reported and 8.1% organic. Second-quarter gross profit margin reached 70.7% versus 67.7% a year earlier, which the company attributes to higher-margin products and a tariff recovery benefit. Neuromodulation grew 14.9% reported in the first half.

Hidden risk.The MD&A itself flags increased competition in Electrophysiology and a deceleration of certain WATCHMAN procedures. Urology grew only 0.6% organically in the first half, hurt by volume-based procurement in China and commercial disruption in sacral neuromodulation. The larger tension is the Penumbra acquisition, valued at approximately $14.5 billion, to be funded with roughly $11.0 billion of newly issued debt plus cash, with the remainder paid in stock. The 2023 Restructuring Plan reached $748 million in cumulative pre-tax charges, and a new global restructuring program was approved on July 21, 2026. Readers may want to look at how the combined debt load and integration costs are reported in later filings.